We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Microsystem Reduces Cost of Developing Ion Channel Drugs

By LabMedica International staff writers
Posted on 11 Dec 2013
The use of a microsystem that generates ion channels in a cell-free medium is expected to boost development of drugs that target these channels in the treatment of diseases such as cystic fibrosis, myasthenia gravis, and epilepsy.

The effect of drugs on ion channels is currently studied by electrophysiology, which measures an electric current across ion channel proteins. More...
This, however, is a slow and expensive process that is carried out using ion channels in living cell membranes.

In a paper published in the October 18, 2013, online edition of the journal Analyst, investigators at the University of Southampton (United Kingdom) in collaboration with colleagues at the University of Quebec (Montreal, Canada) described the development of a cell-free expression mixture that allows ion channels to be inserted into stable artificial "cell membranes."

Results of the study showed that single-channel current measurements of the potassium channels KcsA and hERGS5–S6 could be obtained by direct insertion in interdroplet lipid bilayers from microliters of a cell-free expression medium.

"By putting the ion channel into an artificial membrane, we only have one type of channel, no living cells, and a relatively inexpensive method for testing for several of these types of channels at once," said senior author Dr. Maurits de Planque, lecturer in electronics and computer science at the University of Southampton. "Researchers have experimented with cell-free mixtures before, but they found that this method was not economical due to the amount of expensive biochemicals required. Our proposal to develop a new platform, which uses a couple of microliters instead of milliliters, will be a very cost-effective way of doing this, particularly when the produced channel is directly inserted in a membrane for drug testing."

Related Links:

University of Southampton
University of Quebec



Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
Steam Sterilizer
Hi Vac II Line
Repetitive Pipette
VWR® Stepper Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Characterization of EV separated by distinct methods (Photo courtesy of Yuanyuan Liu, Yanbin Guo et al. Engineering, doi.org/10.1016/j.eng.2025.12.009)

Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis

Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read more

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.